Teleflex Incorporated
NYSE•TFX
CEO: Mr. Liam J. Kelly
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1980-03-17
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
連絡先情報
550 East Swedesford Road, Suite 400, Wayne, PA, 19087-1603, United States
610-225-6800
時価総額
$4.79B
PER (TTM)
-5.3
36
配当利回り
1.3%
52週高値
$143.32
52週安値
$100.18
52週レンジ
順位29Top 17.8%
5.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$568.98M+0.00%
直近4四半期の推移
EPS
-$16.15+0.00%
直近4四半期の推移
フリーCF
$151.56M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Continuing Revenue Growth Net revenues reached $1.99B USD, increasing 17.2% driven by $202.4M contribution from the acquired VI Business.
Major Acquisition Completed Completed $825.2M cash acquisition of BIOTRONIK VI business in Q3 2025, adding coronary and peripheral devices.
Significant Asset Impairment Recognized $100.0M impairment charge on Titan SGS intangible assets following a downward revision to future sales forecasts.
Leadership Transition Finalized Stuart Randle appointed Interim President and CEO in January 2026 following the departure of former Chairman Kelly.
リスク要因
Gross Margin Compression Gross margin dropped 480 basis points to 56.2% due to amortization from VI acquisition and increased logistics costs.
Strategic Divestiture Execution Sale of three major businesses is subject to closing adjustments and regulatory approvals expected in the second half of 2026.
Sterilization Supply Chain Risk Disruptions at contract sterilizers using ethylene oxide could impair ability to supply critical medical products.
Competitive Market Pressures Industry consolidation and customer purchasing power may compel price reductions, negatively affecting financial results.
見通し
Portfolio Transformation Underway Agreements signed to sell Acute Care, IU, and OEM businesses for $2.0B cash, expected to close in second half 2026.
Integration Savings Targeted VI Business integration plan estimates $36M to $44M total charges, aiming for $24M to $30M annual pre-tax savings.
Capital Return Strategy Intend to use net divestiture proceeds, approximately $1.8B after-tax, for debt paydown and shareholder repurchases.
ERP System Upgrade Initiated Multi-year phased conversion to upgrade global ERP system is underway, requiring significant personnel and financial resources.
同業比較
売上高 (TTM)
$11.70B
$5.10B
$3.44B
粗利益率 (最新四半期)
100.0%
90.1%
89.8%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| PCVX | $8.09B | -10.0 | -25.9% | 7.5% |
| ARWR | $7.70B | 38.1 | 36.1% | 19.5% |
| KRYS | $7.35B | 35.5 | 18.7% | 0.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-6.7%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月29日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし